{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:38:50Z","timestamp":1791419930982,"version":"4.3.3"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Clinical and real-world studies show that elexacaftor\/tezacaftor\/ivacaftor (ELX\/TEZ\/IVA) is efficacious and safe in people with cystic fibrosis (CF) \u226512 years of age with at least one F508del allele.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Given the potential for lifelong ELX\/TEZ\/IVA use, the long-term safety and efficacy of ELX\/TEZ\/IVA was assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this phase 3, open-label, single-arm extension study, participants with F508del-minimal function genotypes (from 24-wk parent study 445-102 [n\u2009=\u2009399]) or with the F508del-F508del genotype (from 4-wk parent study 445-103 [n\u2009=\u2009107]) received ELX\/TEZ\/IVA (ELX 200 mg once daily, TEZ 100 mg once daily, and IVA 150 mg every 12 h) over 192 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>The primary endpoint was safety and tolerability. Mean exposure to ELX\/TEZ\/IVA was 172.6 weeks. Most participants had adverse events classified as mild (12.8%) or moderate (60.7%) in severity. Eighteen participants (3.6%) had adverse events that led to treatment discontinuation. After starting ELX\/TEZ\/IVA, participants had consistent increases in percent predicted FEV1 (ppFEV1), Cystic Fibrosis Questionnaire\u2013Revised respiratory domain score, and body mass index, with decreases in sweat chloride concentration and pulmonary exacerbation rates; these improvements were maintained through 192 weeks. The mean annualized rate of change in ppFEV1 was 0.02 percentage points (95% confidence interval, \u22120.14 to 0.19) after initiation of ELX\/TEZ\/IVA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>During this 192-week open-label extension study, the longest clinical study of a CFTR (cystic fibrosis transmembrane conductance regulator) modulator to date, ELX\/TEZ\/IVA remained generally safe and well tolerated. Participants had sustained improvements in lung function, respiratory symptoms, CFTR function, pulmonary exacerbation rates, and nutritional status. The estimated annualized rate of change in ppFEV1 suggests no evidence of pulmonary function loss across the study population over the 4-year treatment period. These results confirm the favorable long-term safety profile and durable disease-modifying clinical benefits of ELX\/TEZ\/IVA in adolescents and adults with CF.<\/jats:p>\n                    <jats:p>Clinical trial registered with www.clinicaltrials.gov (NCT03525574).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.202411-2231oc","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T15:15:11Z","timestamp":1744298111000},"page":"1901-1914","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":34,"title":["Long-Term Safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One\n                    <i>F508del<\/i>\n                    Allele: A Phase 3 Open-Label Extension Study"],"prefix":"10.1093","volume":"211","author":[{"given":"Cori L.","family":"Daines","sequence":"first","affiliation":[{"name":"University of Arizona, Banner University Medical Center, Tucson, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8551-3734","authenticated-orcid":false,"given":"Deepika","family":"Polineni","sequence":"additional","affiliation":[{"name":"Washington University in St. Louis, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Tullis","sequence":"additional","affiliation":[{"name":"St. Michael\u2019s Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Costa","sequence":"additional","affiliation":[{"name":"Univeristy of Messina, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6839-0936","authenticated-orcid":false,"given":"Rachel W.","family":"Linnemann","sequence":"additional","affiliation":[{"name":"Emory University, Children\u2019s Healthcare of Atlanta, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4057-2199","authenticated-orcid":false,"given":"Marcus A.","family":"Mall","sequence":"additional","affiliation":[{"name":"Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Germany"},{"name":"German Center for Lung Research, associated partner site Berlin, Berlin, Germany"},{"name":"German Center for Child and Adolescent Health, Partner Site, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5455-8208","authenticated-orcid":false,"given":"Edward F.","family":"McKone","sequence":"additional","affiliation":[{"name":"St. Vincent\u2019s University Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley S.","family":"Quon","sequence":"additional","affiliation":[{"name":"University of British Columbia and St. Paul\u2019s Hospital, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix C.","family":"Ringshausen","sequence":"additional","affiliation":[{"name":"Hannover Medical School and German Center for Lung Research, Hannover, Germany"},{"name":"European Reference Network Respiratory Diseases, Frankfurt\/Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiran","family":"Selvadurai","sequence":"additional","affiliation":[{"name":"The Children\u2019s Hospital at Westmead, Westmead, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Taylor-Cousar","sequence":"additional","affiliation":[{"name":"National Jewish Health, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Withers","sequence":"additional","affiliation":[{"name":"Royal Devon University Hospitals Trust, Exeter, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory S.","family":"Sawicki","sequence":"additional","affiliation":[{"name":"Boston Children\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Lee","sequence":"additional","affiliation":[{"name":"Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Ahluwalia","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Morlando Geiger","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jennings","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyuan Vincent","family":"Tan","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Waltz","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Ramsey","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Hospital, Seattle, Washington; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0113-912X","authenticated-orcid":false,"given":"Matthias","family":"Griese","sequence":"additional","affiliation":[{"name":"Ludwig Maximilian University and German Center for Lung Research, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"2026013020471731200_bib1","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"O\u2019Sullivan","year":"2009","journal-title":"Lancet"},{"key":"2026013020471731200_bib2","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"2026013020471731200_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026013020471731200_bib4","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N Engl J Med"},{"key":"2026013020471731200_bib5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","article-title":"Cystic fibrosis","volume":"10","author":"Mall","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2026013020471731200_bib6","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"key":"2026013020471731200_bib7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1126\/science.1712984","article-title":"Demonstration that CFTR is a chloride channel by alteration of its anion selectivity","volume":"253","author":"Anderson","year":"1991","journal-title":"Science"},{"key":"2026013020471731200_bib8","doi-asserted-by":"crossref","first-page":"15010","DOI":"10.1038\/nrdp.2015.10","article-title":"Cystic fibrosis","volume":"1","author":"Ratjen","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"2026013020471731200_bib9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1146\/annurev.biochem.75.103004.142532","article-title":"CFTR function and prospects for therapy","volume":"77","author":"Riordan","year":"2008","journal-title":"Annu Rev Biochem"},{"key":"2026013020471731200_bib10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13073-024-01316-5","article-title":"Diversity of CFTR variants across ancestries characterized using 454,727 UK biobank whole exome sequences","volume":"16","author":"Ideozu","year":"2024","journal-title":"Genome Med"},{"key":"2026013020471731200_bib11","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1164\/rccm.201910-1943SO","article-title":"Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications","volume":"201","author":"Mall","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026013020471731200_bib12","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"2026013020471731200_bib13","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"2026013020471731200_bib14","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"key":"2026013020471731200_bib15","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026013020471731200_bib16","doi-asserted-by":"crossref","first-page":"e28508","DOI":"10.1016\/j.heliyon.2024.e28508","article-title":"Real-world effectiveness of elexacaftor\/tezacaftor\/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis","volume":"10","author":"Keens","year":"2024","journal-title":"Heliyon"},{"key":"2026013020471731200_bib17","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del","volume":"22","author":"Lopez","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026013020471731200_bib18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026013020471731200_bib19","doi-asserted-by":"crossref","first-page":"e29188","DOI":"10.1016\/j.heliyon.2024.e29188","article-title":"Longitudinal improvements in clinical and functional outcomes following initiation of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis","volume":"10","author":"Vijaykumar","year":"2024","journal-title":"Heliyon"},{"key":"2026013020471731200_bib20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026013020471731200_bib21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1164\/rccm.202201-0219OC","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on lung clearance index and magnetic resonance imaging in patients with cystic fibrosis and one or two F508del alleles","volume":"206","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026013020471731200_bib22","doi-asserted-by":"crossref","first-page":"2201402","DOI":"10.1183\/13993003.01402-2022","article-title":"Lung transplantation for end-stage cystic fibrosis before and after the availability of elexacaftor-tezacaftor-ivacaftor, Germany, 2012-2021","volume":"61","author":"Ringshausen","year":"2023","journal-title":"Eur Respir J"},{"key":"2026013020471731200_bib23","doi-asserted-by":"crossref","first-page":"2202029","DOI":"10.1183\/13993003.02029-2022","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study","volume":"62","author":"Daines","year":"2023","journal-title":"Eur Respir J"},{"key":"2026013020471731200_bib24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1164\/rccm.202301-0021OC","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in children aged \u22656 years with cystic fibrosis and at least one F508del allele: a phase 3, open-label clinical trial","volume":"208","author":"Wainwright","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026013020471731200_bib25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1164\/rccm.202303-0380LE","article-title":"Raised intracranial pressure in three children with cystic fibrosis receiving elexacaftor-tezacaftor-ivacaftor modulator therapy","volume":"208","author":"Southern","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026013020471731200_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1164\/rccm.202305-0785ED","article-title":"Cystic fibrosis: from tragedy to triumph","volume":"208","author":"Ramsey","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026013020471731200_bib27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: interim results of an open-label phase 3 clinical trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026013020471731200_bib28","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jcf.2010.04.002","article-title":"Year-to-year changes in lung function in individuals with cystic fibrosis","volume":"9","author":"Liou","year":"2010","journal-title":"J Cyst Fibros"},{"key":"2026013020471731200_bib29","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S2213-2600(20)30510-5","article-title":"Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study","volume":"9","author":"Flume","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026013020471731200_bib30","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.201503-0578OC","article-title":"Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data","volume":"192","author":"Sawicki","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026013020471731200_bib31","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S2213-2600(14)70218-8","article-title":"Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)","volume":"2","author":"McKone","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2026013020471731200_bib32","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2022.12.009","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on annual rate of lung function decline in people with cystic fibrosis","volume":"22","author":"Lee","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026013020471731200_bib33","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2026013020471731200_bib34","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/ppul.25250","article-title":"Reduction of pulmonary exacerbations in young children with cystic fibrosis during the COVID-19 pandemic","volume":"56","author":"Patel","year":"2021","journal-title":"Pediatr Pulmonol"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/211\/10\/1901\/66621534\/ajrccm_211_10_1901.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/211\/10\/1901\/66621534\/ajrccm_211_10_1901.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T01:47:30Z","timestamp":1769824050000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/211\/10\/1901\/8444236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,1]]},"published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.202411-2231oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"2024-11-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}